AAPL   331.50 (+2.85%)
MSFT   187.20 (+2.34%)
FB   230.77 (+1.98%)
GOOGL   1,440.02 (+1.82%)
AMZN   2,483.00 (+0.91%)
NVDA   356.80 (+1.75%)
CGC   16.51 (-0.72%)
BABA   219.55 (+0.69%)
GE   7.88 (+1.81%)
TSLA   885.66 (+2.46%)
AMD   53.10 (+0.89%)
GILD   76.75 (-1.02%)
NFLX   419.60 (+1.27%)
BAC   28.11 (+4.97%)
BA   205.43 (+11.47%)
AAPL   331.50 (+2.85%)
MSFT   187.20 (+2.34%)
FB   230.77 (+1.98%)
GOOGL   1,440.02 (+1.82%)
AMZN   2,483.00 (+0.91%)
NVDA   356.80 (+1.75%)
CGC   16.51 (-0.72%)
BABA   219.55 (+0.69%)
GE   7.88 (+1.81%)
TSLA   885.66 (+2.46%)
AMD   53.10 (+0.89%)
GILD   76.75 (-1.02%)
NFLX   419.60 (+1.27%)
BAC   28.11 (+4.97%)
BA   205.43 (+11.47%)
AAPL   331.50 (+2.85%)
MSFT   187.20 (+2.34%)
FB   230.77 (+1.98%)
GOOGL   1,440.02 (+1.82%)
AMZN   2,483.00 (+0.91%)
NVDA   356.80 (+1.75%)
CGC   16.51 (-0.72%)
BABA   219.55 (+0.69%)
GE   7.88 (+1.81%)
TSLA   885.66 (+2.46%)
AMD   53.10 (+0.89%)
GILD   76.75 (-1.02%)
NFLX   419.60 (+1.27%)
BAC   28.11 (+4.97%)
BA   205.43 (+11.47%)
AAPL   331.50 (+2.85%)
MSFT   187.20 (+2.34%)
FB   230.77 (+1.98%)
GOOGL   1,440.02 (+1.82%)
AMZN   2,483.00 (+0.91%)
NVDA   356.80 (+1.75%)
CGC   16.51 (-0.72%)
BABA   219.55 (+0.69%)
GE   7.88 (+1.81%)
TSLA   885.66 (+2.46%)
AMD   53.10 (+0.89%)
GILD   76.75 (-1.02%)
NFLX   419.60 (+1.27%)
BAC   28.11 (+4.97%)
BA   205.43 (+11.47%)
Log in

LON:COGCambridge Cognition Share Price, Forecast & News

GBX 26.50
-0.70 (-2.57 %)
(As of 06/5/2020 04:00 PM ET)
Add
Compare
Today's Range
27
Now: GBX 26.50
27.20
50-Day Range
20.50
MA: GBX 24.37
29
52-Week Range
16.50
Now: GBX 26.50
73
Volume21,000 shs
Average Volume40,421 shs
Market Capitalization£8.26 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Cambridge Cognition Holdings Plc, a neuroscience technology company, develops digital health products. The company offers CANTAB Recruit, an online patient recruitment platform for pharmaceutical and biotechnology companies to identify qualified clinical trial participants in high-need indications, such as Alzheimer's disease; CANTAB Connect that provides digital cognitive assessment solutions for pharmaceutical clinical trials in various therapeutic areas from phases I-IV or a cognitive testing software that enhances the chances of success and minimizing the risk of failure in neuroscience research; and Cognition Kit, a digital health platform, which delivers wearable and smartphone apps to provide engaging digital health solutions for the enhancement of patient engagement, demonstration of treatment efficacy, and understanding of a disease and a patient's response to medication. It also provides CANTAB Connect Research, a research software that offers sensitive digital measures of cognitive function for various areas of brain research; CANTAB Mobile, a touchscreen memory test used in clinical research of Alzheimer's disease; CANTAB BrainHealth, an online digital health assessment tool to measure and monitor mental wellbeing and cognitive performance in the workplace; CANTAB Insight, a medical device that helps to determine an individual's cognitive health; and Cognitive health and wellbeing, which Optimize mental wellbeing and performance throughout the life. The company was incorporated in 2012 and is based in Cambridge, the United Kingdom.
Read More
Cambridge Cognition logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 1.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.28 out of 5 stars


Industry, Sector and Symbol

Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone44 1223 810 700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£5.56 million
Cash FlowGBX 8.32 per share
Book ValueGBX 0.30 per share

Profitability

Miscellaneous

Employees73
Market Cap£8.26 million
Next Earnings DateN/A
OptionableOptionable

Receive COG News and Ratings via Email

Sign-up to receive the latest news and ratings for COG and its competitors with MarketBeat's FREE daily newsletter.

Cambridge Cognition (LON:COG) Frequently Asked Questions

How has Cambridge Cognition's stock been impacted by COVID-19 (Coronavirus)?

Cambridge Cognition's stock was trading at GBX 20.20 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, COG stock has increased by 31.2% and is now trading at GBX 26.50. View which stocks have been most impacted by Coronavirus.

How were Cambridge Cognition's earnings last quarter?

Cambridge Cognition Holdings PLC (LON:COG) posted its earnings results on Tuesday, May, 5th. The company reported ($12.40) EPS for the quarter, missing the consensus estimate of ($10.60) by $1.80. View Cambridge Cognition's earnings history.

Has Cambridge Cognition been receiving favorable news coverage?

Media stories about COG stock have been trending positive this week, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cambridge Cognition earned a news sentiment score of 2.8 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutCambridge Cognition.

Who are some of Cambridge Cognition's key competitors?

What other stocks do shareholders of Cambridge Cognition own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cambridge Cognition investors own include Interserve (IRV), Alio Gold (ALO), Concepta (CPT), European Metals (EMH), IntelGenx Technologies (IGXT), Syneos Health (SYNH), Travelers Companies (TRV), Amryt Pharma (AMYT), Altyn (ALTN) and American International Group (AIG).

Who are Cambridge Cognition's key executives?

Cambridge Cognition's management team includes the following people:
  • Dr. Steven John Powell, CEO & Director (Age 58)
  • Mr. Nicholas John Cordeaux Walters, CFO, Sec. & Director (Age 61)
  • Mr. John Hammond, Co-Founder
  • Dr. Matthew Stork, Chief Operating Officer
  • Mr. Nick Taptiklis, Head of Technology Strategy

What is Cambridge Cognition's stock symbol?

Cambridge Cognition trades on the London Stock Exchange (LON) under the ticker symbol "COG."

How do I buy shares of Cambridge Cognition?

Shares of COG and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Cambridge Cognition's stock price today?

One share of COG stock can currently be purchased for approximately GBX 26.50.

How big of a company is Cambridge Cognition?

Cambridge Cognition has a market capitalization of £8.26 million and generates £5.56 million in revenue each year. Cambridge Cognition employs 73 workers across the globe.

What is Cambridge Cognition's official website?

The official website for Cambridge Cognition is www.cambridgecognition.com.

How can I contact Cambridge Cognition?

Cambridge Cognition's mailing address is Tunbridge Court Tunbridge Lane, Bottisham, CAMBRIDGE, CB25 9TU, United Kingdom. The company can be reached via phone at 44 1223 810 700.

This page was last updated on 6/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.